14:00 CET

Oncopeptides Virtual Capital Markets Day

The Program

14.00 – 16.00 CET (8:00am-10am EST) November 30th, 2020


“Building a Fully Integrated Biotechnology Company”

  • Introduction and Strategy for Value Growth – Marty J Duvall, CEO Oncopeptides
  • Multiple Myeloma
    “Myeloma remains one of the largest unmet medical needs within hematology”
    o Assistant Professor Joshua Richter, MD. Icahn School of Medicine at Mount Sinai Hospital, New York
  • Relapsed refractory multiple myeloma and melflufen – clinical experience with melflufen – Panel discussion
    o Professor Paul Richardson, MD, Dana-Farber Cancer Institute, Boston
    o Associate Professor Maria-Victoria Mateos, MD, PhD, University Hospital, Salamanca
    Moderated by Klaas Bakker, MD, PhD, CMO Oncopeptides
  • The clinical development program for melflufen
    “Understanding how melflufen can help patients the most” – Jakob Lindberg, CSO Oncopeptides
  • Successfully making the drug available for patients in the US
    Overview of US launch of melflufen – Marty J Duvall, CEO Oncopeptides
  • Questions and Answers


The CMD will be webcasted live on the link:https://tv.streamfabriken.com/oncopeptides-cmd-2020

Upcoming events

European Myeloma Network Meeting 2021


Virtual meeting postponed to 3-6 March, 2021. The EMN meeting will be held in the virtual modality, on 3-6 March 2021.

Carnegie Healthcare Conference


47th Annual Meeting of the EBMT


The European Society for Blood and Marrow Transplantation 2021.

AACR Annual Meeting 2021


Virtual Meeting Week 1: April 10-15; Week 2: May 17-21

European School of Haematology E-conference 2021


E-Conference - How to Diagnose and Treat Multiple Myeloma.

COMy 2021


World Congress on Controversies in Multiple Myeloma 2021.

ASCO 2021 Annual Meeting


American Society of Clinical Oncology (ASCO) 2021.

EHA 2021 Virtual Congress


European Hematology Association Annual meeting 2021.

Interim Report Q2 2021

08:00 CET

Interim Report Q3 2021

08:00 CET